News & Views | Published:

Protein degradation

Prime time for PROTACs

Nature Chemical Biology volume 11, pages 634635 (2015) | Download Citation

  • A Corrigendum to this article was published on 20 October 2015

This article has been updated

PROTACs are heterobifunctional small molecules that simultaneously bind a target protein and a ubiquitin ligase, enabling ubiquitination and degradation of the target. Major progress in developing potent and specific PROTACs has recently been reported, invigorating prospects for novel PROTAC-based therapies.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 23 September 2015

    In the version of this article originally published, the protein ERRα was mislabeled as BRD4 in Figure 1 and its legend, and the citation of the figure in the text was misplaced. These errors have been corrected in the HTML and PDF versions of the article.

References

  1. 1.

    et al. Proc. Natl. Acad. Sci. USA 98, 8554–8559 (2001).

  2. 2.

    & Angew. Chem. Int. Edn. Engl. 53, 2312–2330 (2014).

  3. 3.

    et al. ACS Chem. Biol. (2015).

  4. 4.

    et al. Chem. Biol. 22, 755–763 (2015).

  5. 5.

    et al. Science 348, 1376–1381 (2015).

  6. 6.

    , & ACS Chem. Biol. (2015).

  7. 7.

    et al. Nat. Chem. Biol. 11, 611–617 (2015).

  8. 8.

    et al. Science 327, 1345–1350 (2010).

  9. 9.

    et al. Science 343, 301–305 (2014).

  10. 10.

    et al. Science 343, 305–309 (2014).

  11. 11.

    et al. Br. J. Haematol. 164, 811–821 (2014).

  12. 12.

    et al. Nature 512, 49–53 (2014).

  13. 13.

    et al. Nat. Struct. Mol. Biol. 21, 803–809 (2014).

Download references

Author information

Affiliations

  1. Raymond J. Deshaies is in the Howard Hughes Medical Institute and Division of Biology and Biological Engineering, Caltech, Pasadena, California, USA.

    • Raymond J Deshaies

Authors

  1. Search for Raymond J Deshaies in:

Competing interests

R.J.D. is co-founder of a company (Cleave Biosciences) that is developing therapeutics based on targeting enzymes in the ubiquitin-proteasome pathway. R.J.D. also holds stock in Cleave Biosciences and serves as a consultant and member of their Scientific Advisory Board.

Corresponding author

Correspondence to Raymond J Deshaies.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nchembio.1887

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing